{"data":{"type":"feed_item","id":344511,"entity_id":"wefunder:feed_item:344511","attributes":{"canonical_url":"https://wefunder.com/feed/344511","retrieval_urls":{"canonical":"https://wefunder.com/feed/344511","json":"https://wefunder.com/feed/344511.json","markdown":"https://wefunder.com/feed/344511.md","ai_json":"https://wefunder.com/feed/344511.ai.json","ai_text":"https://wefunder.com/feed/344511.ai.txt","changelog_json":"https://wefunder.com/feed/344511.changelog.json","schema":"https://wefunder.com/.well-known/ai-profile-schema.json"},"updated_at":"2026-06-29T10:02:41.363Z","generated_at":"2026-07-14T10:55:12Z","profile_visibility":"public","feed_item":{"id":344511,"entity_id":"wefunder:feed_item:344511","type":"FeedItem::Update","title":"Two New Patents — Extending Our Platform into Cancer Immunotherapy and ALDH2 Deficiency | Sen-Jam Pharmaceutical","content_plain":"Dear WeFunder Investors and Community, A quick update on our intellectual property. In June we filed two new U.S. provisional patent applications, broadening the portfolio around Sen-Jam’s anti-inflammatory platform. SJP-015PR — immune-related adv...","published_at":"2026-06-27T19:30:18.334Z","updated_at":"2026-06-29T10:02:41.363Z","canonical_url":"https://wefunder.com/feed/344511","author":{"name":"Jim Iversen","profile_url":"https://wefunder.com/jimiversen2"},"subject":{"name":"Sen-Jam Pharmaceutical","profile_url":"https://wefunder.com/senjam"}},"provenance":{"source":"wefunder_public_feed_item","last_verified_at":"2026-06-29T10:02:41Z","claims":{"title":{"source":"feed_item.title","last_verified_at":"2026-06-29T10:02:41Z","as_of":"2026-06-29T10:02:41Z","confidence":"high"},"published_at":{"source":"feed_item.published_at","last_verified_at":"2026-06-29T10:02:41Z","as_of":"2026-06-27T19:30:18Z","confidence":"high"}}}}}}